在加拿大,结直肠癌患者对生物标志物测试的经验如何? :一个混合方法研究研究
Elijah Tongol1,2, Preet Kang1,2, Vicki Cheng1,2
1Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
BMC cancer
|August 31, 2024
概括
大多数结肠直肠癌 (CRC) 患者都知道生物标志物测试,但获得和理解仍然是障碍. 提高患者意识和获得生物标志物测试的机会对于个性化CRC治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 患者体验研究 研究研究
背景情况:
- 生物标志物测试指南针对结直肠癌 (CRC) 的向疗法,增强治疗特异性.
- 了解患者的观点对于优化生物标志物测试融入CRC护理至关重要.
研究的目的:
- 探索加拿大患者关于结直肠癌生物标志物测试的经验和观点.
主要方法:
- 一项混合方法研究,涉及被诊断患有CRC的成年人.
- 通过对意识和经验的在线调查收集的定量数据.
- 通过对调查受访者进行半结构化访谈收集的定性数据.
主要成果:
- 76%的受访者知道生物标志物测试; 67%接受过测试.
- 测试的障碍包括不被提供,成本和焦虑.
- 虽然89%的人认为测试是有用的,但只有一半的人理解了他们的报告.
结论:
- 患者的观点为结直肠癌生物标志物测试提供了关键的见解.
- 提高对生物标志物测试的认识,获取和理解是至关重要的.
- 需要利益相关者的协作努力来应对已识别的挑战.
更多相关视频
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
13.9K
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
8.9K
相关概念视频
Serum Laboratory Studies, Stool Test, Breath Test
324
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
324
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
